Drug efflux transporters such as P-glycoprotein (P-gp) help maintain cellular homeostasis but are also major contributors to the development of multidrug resistance (MDR) phenomena. Since P-gp was associated with MDR, several compounds showing potential to inhibit this transporter have been identified. Particular attention has been given to natural products, namely those of plant origin, looking for highly effective and safe P-gp inhibitors with little to no interaction with other cellular or metabolic processes. Here we abridge several examples of plant compounds from distinct classes, polyketides, lignans, anthraquinones, coumarins, alkaloids, mono- and sesqui-terpenes, steroids and limonoids, which have shown the ability to modulate in vitro or in vivo the P-gp activity.
FerreiraA., PousinhoS., FortunaA., FalcãoA., AlvesG. (2015) Flavonoid compounds as reversal agents of the P-glycoprotein-mediated multidrug resistance: biology, chemistry and pharmacology. Phytochemistry Reviews, 14, 233–272.
2.
PrajapatiR., SangamwarA.T. (2014) Translocation mechanism of P-glycoprotein and conformational changes occurring at drug-binding site: Insights from multi-targeted molecular dynamics. Biochimica et Biophysica Acta, 1838, 2882–2898.
3.
GramattéT., OertelR. (1999) Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clinical Pharmacology and Therapeutics, 66, 239–245.
4.
BalayssacD., AuthierN., CayreA., CoudoreF. (2005) Does inhibition of P-glycoprotein lead to drug-drug interactions?Toxicology Letters, 156, 319–329.
5.
FortunaA., AlvesG., FalcãoA. (2011) In vitro and in vivo relevance of the P-glycoprotein probe substrates in drug discovery and development: Focus on rhodamine 123, digoxin and talinolol. Journal of Bioequivalence and Bioavailability, S2, 1–23.
6.
MillwardM.J., CantwellB.M.J., MunroN.C., RobinsonA., CorrisP.A., HarrisA.L. (1993) Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomized study. British Journal of Cancer, 67, 1031–1035.
7.
YangK., WuJ., LiX. (2008) Review: Recent advances in research on P-glycoprotein inhibitors. BioScience Trends, 2, 137–146.
8.
PinedoH.M., GiacconeG., SikoraK. (2007) Drug Resistance in the Treatment of Cancer.Cambridge University Press, Cambridge.
9.
MichischG.H., NoordzijM.A., GaastAvd, GebreamlackP., KöhrmannK.U., Mogler-DrautzE., KupperH., SchröderF.H. (1995) Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 121, R11–R16.
10.
PalmeiraA., SousaE., VasconcelosM.H., PintoM.M. (2012) Three decades of P-gp inhibitors: Skimming through several generations and scaffolds. Current Medicinal Chemistry, 19, 1946–2025.
11.
MunagalaS., SirasaniG., KokkondaP., PhadkeM., KrynetskaiaN., LuP., SharomF.J., ChaudhuryS., AbdulhameedM., TawaG., WallqvistA., MartinezR., ChildersW., Abou-GharbiaM., KrynetskiyE., AndradeR.B. (2014) Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorganic & Medicinal Chemistry, 22, 1148–1155.
12.
ShenJ., CuiY., GuJ., LiY., LiL. (2014) A genetic algorithm-back propagation artificial neural network model to quantify the affinity of flavonoids toward P-glycoprotein. Combinatorial Chemistry & High Throughput Screening, 17, 162–172.
13.
NabekuraT., KamiyamaS., KitagawaS. (2005) Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochemical and Biophysical Research Communications, 327, 866–870.
14.
NabekuraT. (2010) Review: Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins, 2, 1207–1224.
15.
GoelA., KunnumakkaraA.B., AggarwalB.B. (2008) Curcumin as “Curecumin”: From kitchen to clinic. Biochemical Pharmacology, 75, 787–809.
16.
ShuklaY., SinghM. (2007) Cancer preventive properties of ginger: A brief review. Food and Chemical Toxicology, 45, 683–690.
17.
LiangY., ZhouY., ZhangJ., LiuY., GuanT., WangY., XingL., RaoT., ZhouL., HaoK., XieL., WangG. (2013) In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein. Phytomedicine, 20, 1030–1038.
18.
SuS., ChengX., WinkM. (2015) Natural lignans from Arctium lappa modulate P-glycoprotein efflux function in multidrug resistant cancer cells. Phytomedicine, 22, 301–307.
19.
HanH.K., AnhL.T.V. (2012) Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis.Anticancer Research, 32, 4445–4452.
20.
SukhaphiromN., VardhanabhutiN., ChirdchupunsereeH., PramyothinP., JianmongkolS. (2012) Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. Journal of Pharmacy and Pharmacology, 65, 292–299.
21.
ChoiR.J., NgocT.M., BaeK., ChoH.J., KimD.D., ChunJ., KhanS., KimY.S. (2013) Anti-inflammatory properties of anthraquinones and their relationship with the regulation of P-glycoprotein function and expression. European Journal of Pharmaceutical Sciences, 48, 272–281.
22.
PengY.H., LinS.P., YuC.P., TsaiS.Y., ChenM.Y., HouY.C., ChaoP.D.L. (2014) Serum concentrations of anthraquinones after intake of Folium Sennae and potential modulation on P-glycoprotein. Planta Medica, 80, 1291–1297.
23.
WangM.T., LiI.H., LeeW.J., HuangT.Y., LeuH.B., ChanA.L. (2011) Exposure to sennoside-digoxin interaction and risk of digoxin toxicity: a population based nested case-control study. European Journal of Heart Failure, 13, 1238–1243.
24.
NabekuraT., YamakiT., KitagawaS. (2008) Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. European Journal of Pharmacology, 600, 45–49.
25.
KasaianJ., MosaffaF., BehravanJ., MasulloM., PiacenteS., GhandadiM., IranshahiM. (2015) Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. Fitoterapia, 103, 149–154.
26.
EidS.Y., El-ReadiM.Z., EldinE., FataniS.H., WinkM. (2013) Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells. Phytomedicine, 21, 47–61.
27.
BhardwajR.K., GlaeserH., BecquemontL., KlotzU., GuptaS.K., FrommM.F. (2002) Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. Journal of Pharmacology and Experimental Therapeutics, 302, 645–650.
28.
HanY., TanT.M.C., LimL.Y. (2008) In vitro and in vivo evaluation on the effects of piperine on P-gp function and expression. Toxicology and Applied Pharmacology, 230, 283–289.
29.
HanY., TanT.M.C., LimL.Y. (2006) Effects of capsaicin on P-gp function and expression in Caco-2 cells. Biochemical Pharmacology, 71, 1727–1734.
30.
MaY., WinkM. (2008) Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells. Phytomedicine, 15, 754–758.
31.
WinkM. (2008) Evolutionary advantage and molecular modes of action of multi-component mixtures used in phytomedicine. Current Drug Metabolism, 9, 996–1009.
32.
WinkM., AshourM.L., El-ReadiM.Z. (2012) Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents. Frontiers in Microbiology, 3, article 130, 1-15.
33.
YoshidaN., TakagiA., KitazawaH., KawakamiJ., AdachiI. (2005) Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli Fructus.Toxicology and Applied Pharmacology, 209, 169–173.
34.
PeresteloN.R., Sánchez-CañeteM.P., GamarroF., JiménezI.A., CastanysS., BazzocchiI.L. (2011) Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes. European Journal of Medicinal Chemistry, 46, 4915–4923.
35.
NabekuraT., YamakiT., HiroiT., UenoK., KitagawaS. (2010) Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacological Research, 61, 259–263.
36.
NabekuraT., YamakiT., UenoK., KitagawaS. (2008) Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochemical and Biophysical Research Communications, 369, 363–368.
37.
ZeinoM., PaulsenM.S., ZehlM., UrbanE., KoppB., EfferthT. (2015) Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids. Biochemical Pharmacology, 93, 11–24.
38.
AbdallahH.M., Al-AbdA.M., El-DineR.S., El-HalawanyA.M. (2015) P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. Journal of Advanced Research, 6, 45–62.
El-ReadiM.Z., HamdanD., FarragN., El-ShazlyA., WinkM. (2010) Inhibition of P-glycoprotein activity by limonin and other secondary metabolites in human colon and leukaemia cell lines. European Journal of Pharmacology, 626, 139–145.
